# Pizarra — PT-pseudo_138092c2a6be (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_138092c2a6be
Task: 1

Encounter: Urology - outpatient on 22 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 52-year-old male
  - PSA: 9.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.16 ng/mL²
  - PSA velocity: 1.13 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 58.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86231947 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Hypertension, Obesity (BMI >30), Osteoarthritis
  - Current medication: amlodipine, lisinopril, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 9 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 58 mL. csPCa 0.86.

Vitals: weight 92 kg, height 191 cm, BMI 25.2, BP 134/69 mmHg, HR 75 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Clinical reassessment is required due to a confirmed prior biopsy and a continuing upward PSA trend.

History: First noted for an elevated PSA reading in 2022, this patient has since been managed within the outpatient setting. At fifty-two years of age, he works as a retired shopkeeper, lives with his wife in an assisted-living residence, and navigates daily life using a mobility frame. Moderate lower urinary tract symptoms yield an IPSS score of 16, yet he sustains a rigorous cycling regimen of roughly 30 kilometres three times weekly and restricts alcohol intake to five units per week. His medical background includes hypertension, Obesity (BMI >30), and osteoarthritis, managed with amlodipine, lisinopril, and paracetamol taken as needed. He remains a Current smoker (45 pack-yr). A recent routine surveillance colonoscopy returned normal results, and he reports no fresh pelvic pain or haematuria. A prior systematic biopsy identified low-volume disease, and his PSA continues to climb.

Physical examination: DRE: The prostate presents as symmetrically enlarged with a smooth, firm texture, lacking any palpable nodules or asymmetry. Vital signs remain stable, recording a blood pressure of 134/69 mmHg and a heart rate of 75 bpm. General observation shows a well-nourished individual walking with a standard mobility frame, exhibiting no acute distress or peripheral swelling.

Patient info: retired shopkeeper; Married; Lives in assisted-living facility.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.41 +/- 0.20   (95% CI 0.07-0.81)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 5.0 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=9.0, age=52.0, psad=0.16, dre_ord=0.0, vol=58.0, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (1.13 ng/mL/yr) and the prior PSA (7.9 ng/mL), which indicate a significant upward trend, against the PI-RADS 4 score and the prior positive biopsy status. It also missed the context provided by the clinical notes regarding the low-volume disease identified previously and the patient's specific clinical presentation (e.g., LUTS score, DRE findings).

WHY THE SUGGESTION COULD BE WRONG
  The prior suggestion of "NO BIOPSY" has a wide uncertainty interval (0.41 +/- 0.20), placing it in the 'discuss' tier. This suggests the input data is ambiguous. A failure mode is the contradiction between the high csPCa predicted probability (0.86231947) and the normal DRE findings, which might be misleading if the prior positive biopsy was for low-volume disease. Another failure mode is ignoring the rising PSA trend (from 7.9 to 9.0 ng/mL) in favor of the static PI-RADS 4 score.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant clinically significant cancer on MRI, it would strongly push towards biopsy.
  <document> PSA history (trend) -> If the trend is highly aggressive (e.g., very high velocity), it would increase the need for further investigation.
  <document> previous GP / urology consultation notes -> These notes might clarify the context of the prior positive biopsy and the clinical significance of the LUTS score.
  <document> laboratory results (full panel) -> This could provide context on other markers that might influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_138092c2a6be", "radiology_report": "Maastricht UMC+ | Imaging Department | 15 February 2025 | multiparametric MRI prostate\n\nClinical request focuses on re-evaluation for a PSA reading of 9.0 ng/mL alongside a previously positive biopsy.\n\nProstatic volume registers at 58.0 mL. T2-weighted sequences highlight a roughly 18 mm focal hypointense area located at the base-to-mid junction of the left peripheral zone. Diffusion-weighted imaging shows restricted diffusion paired with corresponding ADC hypointensity. Dynamic contrast studies demonstrate early focal enhancement compared to adjacent tissue. Seminal vesicles appear normal. No extracapsular extension or suspicious lymphadenopathy is visualized.\n\nPI-RADS 4 lesion in the left peripheral zone.\nPSA density: 0.16 ng/mL/mL.\ncsPCa predicted probability 0.86231947."}

  **psa_trend**
  {"case_id": "PT-pseudo_138092c2a6be", "psa_trend": [{"date": "Jun 2022", "val": 1.7}, {"date": "Feb 2023", "val": 2.6}, {"date": "Oct 2023", "val": 3.9}, {"date": "Jun 2024", "val": 5.9}, {"date": "Feb 2025", "val": 9.0}]}

  **previous_notes**
  {"case_id": "PT-pseudo_138092c2a6be", "previous_notes": [{"date": "01 Sep 2023", "author": "Dr. C. Peters (GP)", "text": "Clinical review highlighted a sustained PSA increase, currently tracking at 5.6 ng/mL after a mid-2022 baseline of 4.8 ng/mL. Rectal palpation showed no abnormalities, and acute retention was absent. The case was forwarded to urology to initiate comprehensive evaluation and imaging planning."}]}

  **lab_results**
  {"case_id": "PT-pseudo_138092c2a6be", "laboratory_results": [{"name": "PSA", "val": "9.0 ng/mL", "date": "20 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.24 ng/mL", "date": "20 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "25%", "date": "20 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "13.7 g/dL", "date": "20 Jan 2025", "flag": ""}, {"name": "WBC", "val": "6.9 x10^9/L", "date": "20 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "263 x10^9/L", "date": "20 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "74 umol/L", "date": "20 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "20 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "17.3 nmol/L", "date": "20 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "54 U/L", "date": "20 Jan 2025", "flag": ""}, {"name": "LDH", "val": "156 U/L", "date": "20 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "6.5 %", "date": "20 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA velocity: 1.13 ng/mL/yr (from initial prompt data, confirmed by trend data)
  - PI-RADS 4 lesion in the left peripheral zone (from MRI report)
  - csPCa predicted probability: 0.86231947

  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)

WHERE THIS LEANS
  The evidence strongly points towards further investigation due to the combination of a high-risk MRI finding (PI-RADS 4) and a significant rising PSA velocity, which contradicts the initial statistical prior of "NO BIOPSY".

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging and rising biochemical markers. The evidence is driven by the PI-RADS 4 lesion in the left peripheral zone and the significant PSA velocity of 1.13 ng/mL/yr, which strongly contradicts the initial statistical prior. The combination of a PI-RADS 4 finding and a rising PSA trend justifies further tissue sampling in this context.

Variables that carried weight: bx=noted, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
